Extension Study Evaluating The Safety And Tolerability of AMX0035
Study sponsor: Amylyx Pharmaceuticals Inc. · AMLX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-10-16Actual
Enrollment · participants352Actual
Source updated2025-01-13Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.